Compared to laser photocoagulation, anti-VEGF therapy may promote rapid regression of ROP, allow for retinal vascularization, and risk retreatment because of recurrent neovascularization, persistent peripheral avascularity, or fibrotic proliferation [7–10]. The gene discussed is VEGFA; the disease is retinopathy of prematurity.